Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 8 |
| List of Tables | 9 | 1 |
| List of Figures | 9 | 1 |
| Omeros Corporation Snapshot | 10 | 1 |
| Omeros Corporation Overview | 10 | 1 |
| Key Information | 10 | 1 |
| Key Facts | 10 | 1 |
| Omeros Corporation Research and Development Overview | 11 | 7 |
| Key Therapeutic Areas | 11 | 7 |
| Omeros Corporation Pipeline Review | 18 | 2 |
| Pipeline Products by Stage of Development | 18 | 1 |
| Pipeline Products Monotherapy | 19 | 1 |
| Omeros Corporation Pipeline Products Glance | 20 | 6 |
| Omeros Corporation Late Stage Pipeline Products | 20 | 1 |
| Phase III Products/Combination Treatment Modalities | 20 | 1 |
| Omeros Corporation Clinical Stage Pipeline Products | 21 | 1 |
| Phase II Products/Combination Treatment Modalities | 21 | 1 |
| Omeros Corporation Early Stage Pipeline Products | 22 | 1 |
| Preclinical Products/Combination Treatment Modalities | 22 | 3 |
| Discovery Products/Combination Treatment Modalities | 25 | 1 |
| Omeros Corporation Drug Profiles | 26 | 69 |
| OMS-721 | 26 | 1 |
| Product Description | 26 | 1 |
| Mechanism of Action | 26 | 1 |
| R&D Progress | 26 | 2 |
| OMS-405 | 28 | 1 |
| Product Description | 28 | 1 |
| Mechanism of Action | 28 | 1 |
| R&D Progress | 28 | 1 |
| OMS-824 | 29 | 1 |
| Product Description | 29 | 1 |
| Mechanism of Action | 29 | 1 |
| R&D Progress | 29 | 1 |
| Monoclonal Antibodies for Oncology, Metabolic, Cardiovascular and Musculoskeletal Disorders | 30 | 1 |
| Product Description | 30 | 1 |
| Mechanism of Action | 30 | 1 |
| R&D Progress | 30 | 2 |
| Monoclonal Antibodies to Inhibit MASP-2 for Rheumatoid Arthritis and Diabetic Complications | 32 | 1 |
| Product Description | 32 | 1 |
| Mechanism of Action | 32 | 1 |
| R&D Progress | 32 | 2 |
| OMS-527 | 34 | 1 |
| Product Description | 34 | 1 |
| Mechanism of Action | 34 | 1 |
| R&D Progress | 34 | 2 |
| OMS-616 | 36 | 1 |
| Product Description | 36 | 1 |
| Mechanism of Action | 36 | 1 |
| R&D Progress | 36 | 2 |
| OMS-906 | 38 | 1 |
| Product Description | 38 | 1 |
| Mechanism of Action | 38 | 1 |
| R&D Progress | 38 | 1 |
| Small Molecule to Agonize GPR52 for Schizophrenia | 39 | 1 |
| Product Description | 39 | 1 |
| Mechanism of Action | 39 | 1 |
| R&D Progress | 39 | 1 |
| Small Molecule to Agonize PTH-1R for Osteoporosis | 40 | 1 |
| Product Description | 40 | 1 |
| Mechanism of Action | 40 | 1 |
| R&D Progress | 40 | 1 |
| Small Molecule to Antagonize GPR101 for Appetite Disorders | 41 | 1 |
| Product Description | 41 | 1 |
| Mechanism of Action | 41 | 1 |
| R&D Progress | 41 | 1 |
| Small Molecule to Antagonize GPR12 for Obesity, Cognitive Impairments and Motor Disorders | 42 | 1 |
| Product Description | 42 | 1 |
| Mechanism of Action | 42 | 1 |
| R&D Progress | 42 | 1 |
| Small Molecule to Antagonize GPR139 for Motor Disorders | 43 | 1 |
| Product Description | 43 | 1 |
| Mechanism of Action | 43 | 1 |
| R&D Progress | 43 | 1 |
| Small Molecule to Antagonize GPR15 for Rheumatoid Arthritis and HIV-Mediated Enteropathy | 44 | 1 |
| Product Description | 44 | 1 |
| Mechanism of Action | 44 | 1 |
| R&D Progress | 44 | 1 |
| Small Molecule to Antagonize GPR161 for Oncology, Ophthalmology and Central Nervous System Disorders | 45 | 1 |
| Product Description | 45 | 1 |
| Mechanism of Action | 45 | 1 |
| R&D Progress | 45 | 1 |
| Small Molecule to Antagonize GPR17 for Central Nervous System Disorders | 46 | 1 |
| Product Description | 46 | 1 |
| Mechanism of Action | 46 | 1 |
| R&D Progress | 46 | 1 |
| Small Molecule to Antagonize GPR173 for Obesity and Schizophrenia | 47 | 1 |
| Product Description | 47 | 1 |
| Mechanism of Action | 47 | 1 |
| R&D Progress | 47 | 1 |
| Small Molecule to Antagonize GPR182 for Pancreatic Cancer | 48 | 1 |
| Product Description | 48 | 1 |
| Mechanism of Action | 48 | 1 |
| R&D Progress | 48 | 1 |
| Small Molecule to Antagonize GPR19 for Metastatic Melanoma and Lung Cancer | 49 | 1 |
| Product Description | 49 | 1 |
| Mechanism of Action | 49 | 1 |
| R&D Progress | 49 | 1 |
| Small Molecule to Antagonize GPR20 for Gastro-Intestinal Stromal Tumors and Acute Myeloid Leukemia | 50 | 1 |
| Product Description | 50 | 1 |
| Mechanism of Action | 50 | 1 |
| R&D Progress | 50 | 1 |
| Small Molecule to Antagonize GPR27 for Obesity, Diabetes and Schizophrenia | 51 | 1 |
| Product Description | 51 | 1 |
| Mechanism of Action | 51 | 1 |
| R&D Progress | 51 | 1 |
| Small Molecule to Antagonize GPR31 for Anxiety Disorders | 52 | 1 |
| Product Description | 52 | 1 |
| Mechanism of Action | 52 | 1 |
| R&D Progress | 52 | 1 |
| Small Molecule to Antagonize GPR39 for Esophageal Squamous Cell Carcinoma and Obesity-Related Type-2 Diabetes | 53 | 1 |
| Product Description | 53 | 1 |
| Mechanism of Action | 53 | 1 |
| R&D Progress | 53 | 1 |
| Small Molecule to Antagonize GPR78 for Bipolar Disorder and Schizophrenia | 54 | 1 |
| Product Description | 54 | 1 |
| Mechanism of Action | 54 | 1 |
| R&D Progress | 54 | 1 |
| Small Molecule to Antagonize GPR85 for Obesity and Schizophrenia | 55 | 1 |
| Product Description | 55 | 1 |
| Mechanism of Action | 55 | 1 |
| R&D Progress | 55 | 1 |
| Small Molecule to Antagonize GPR87 for Oncology | 56 | 1 |
| Product Description | 56 | 1 |
| Mechanism of Action | 56 | 1 |
| R&D Progress | 56 | 1 |
| Small Molecule to Antagonize NMUR2 for Pain | 57 | 1 |
| Product Description | 57 | 1 |
| Mechanism of Action | 57 | 1 |
| R&D Progress | 57 | 2 |
| Small Molecule to Antagonize OPN4 for Circadian Rhythm Irregularities and Sleep Disorders | 59 | 1 |
| Product Description | 59 | 1 |
| Mechanism of Action | 59 | 1 |
| R&D Progress | 59 | 1 |
| Small Molecule to Antagonize P2Y8 for Acute Lymphoblastic Leukemia and Lymphoma | 60 | 1 |
| Product Description | 60 | 1 |
| Mechanism of Action | 60 | 1 |
| R&D Progress | 60 | 1 |
| Small Molecule to Inhibit CCRL2 for Rheumatoid Arthritis and Immune Disorders | 61 | 1 |
| Product Description | 61 | 1 |
| Mechanism of Action | 61 | 1 |
| R&D Progress | 61 | 1 |
| Small Molecule to Target GPR132 for Cardiovascular Diseases | 62 | 1 |
| Product Description | 62 | 1 |
| Mechanism of Action | 62 | 1 |
| R&D Progress | 62 | 1 |
| Small Molecule to Target GPR135 | 63 | 1 |
| Product Description | 63 | 1 |
| Mechanism of Action | 63 | 1 |
| R&D Progress | 63 | 1 |
| Small Molecule to Target GPR141 for Respiratory and Immune Disorders | 64 | 1 |
| Product Description | 64 | 1 |
| Mechanism of Action | 64 | 1 |
| R&D Progress | 64 | 1 |
| Small Molecule to Target GPR150 for Ovarian Cancer | 65 | 1 |
| Product Description | 65 | 1 |
| Mechanism of Action | 65 | 1 |
| R&D Progress | 65 | 1 |
| Small Molecule to Target GPR151 for CNS Diseases | 66 | 1 |
| Product Description | 66 | 1 |
| Mechanism of Action | 66 | 1 |
| R&D Progress | 66 | 1 |
| Small Molecule to Target GPR153 for Schizophrenia | 67 | 1 |
| Product Description | 67 | 1 |
| Mechanism of Action | 67 | 1 |
| R&D Progress | 67 | 1 |
| Small Molecule to Target GPR162 for Neuropsychiatric Disorders | 68 | 1 |
| Product Description | 68 | 1 |
| Mechanism of Action | 68 | 1 |
| R&D Progress | 68 | 1 |
| Small Molecule to Target GPR171 for Eating and Hematological Disorders | 69 | 1 |
| Product Description | 69 | 1 |
| Mechanism of Action | 69 | 1 |
| R&D Progress | 69 | 1 |
| Small Molecule to Target GPR174 for Immunology, Neurology and Oncology | 70 | 1 |
| Product Description | 70 | 1 |
| Mechanism of Action | 70 | 1 |
| R&D Progress | 70 | 1 |
| Small Molecule to Target GPR183 for Osteoporosis and Epstein-Barr Viral Infections | 71 | 1 |
| Product Description | 71 | 1 |
| Mechanism of Action | 71 | 1 |
| R&D Progress | 71 | 1 |
| Small Molecule to Target GPR21 for Obesity and Diabetes | 72 | 1 |
| Product Description | 72 | 1 |
| Mechanism of Action | 72 | 1 |
| R&D Progress | 72 | 1 |
| Small Molecule to Target GPR22 for Anxiety, Cardiovascular Diseases and Osteoarthritis | 73 | 1 |
| Product Description | 73 | 1 |
| Mechanism of Action | 73 | 1 |
| R&D Progress | 73 | 1 |
| Small Molecule to Target GPR25 for Arterial Stiffness | 74 | 1 |
| Product Description | 74 | 1 |
| Mechanism of Action | 74 | 1 |
| R&D Progress | 74 | 1 |
| Small Molecule to Target GPR32 for Acute Inflammation | 75 | 1 |
| Product Description | 75 | 1 |
| Mechanism of Action | 75 | 1 |
| R&D Progress | 75 | 1 |
| Small Molecule to Target GPR37 for Parkinson's Disease | 76 | 1 |
| Product Description | 76 | 1 |
| Mechanism of Action | 76 | 1 |
| R&D Progress | 76 | 1 |
| Small Molecule to Target GPR37L1 for Hypertension and Cardiac Hypertrophy | 77 | 1 |
| Product Description | 77 | 1 |
| Mechanism of Action | 77 | 1 |
| R&D Progress | 77 | 1 |
| Small Molecule to Target GPR45 | 78 | 1 |
| Product Description | 78 | 1 |
| Mechanism of Action | 78 | 1 |
| R&D Progress | 78 | 1 |
| Small Molecule to Target GPR50 for CNS and Metabolic Disorders | 79 | 1 |
| Product Description | 79 | 1 |
| Mechanism of Action | 79 | 1 |
| R&D Progress | 79 | 1 |
| Small Molecule to Target GPR63 for Autism | 80 | 1 |
| Product Description | 80 | 1 |
| Mechanism of Action | 80 | 1 |
| R&D Progress | 80 | 1 |
| Small Molecule to Target GPR65 for Oncology and Inflammatory Disorders | 81 | 1 |
| Product Description | 81 | 1 |
| Mechanism of Action | 81 | 1 |
| R&D Progress | 81 | 1 |
| Small Molecule to Target GPR80 for Hepatocellular Carcinoma | 82 | 1 |
| Product Description | 82 | 1 |
| Mechanism of Action | 82 | 1 |
| R&D Progress | 82 | 1 |
| Small Molecule to Target GPR82 for Appetite Disorders and Body Weight | 83 | 1 |
| Product Description | 83 | 1 |
| Mechanism of Action | 83 | 1 |
| R&D Progress | 83 | 1 |
| Small Molecule to Target GPR83 for CNS and Immunological Disorders | 84 | 1 |
| Product Description | 84 | 1 |
| Mechanism of Action | 84 | 1 |
| R&D Progress | 84 | 1 |
| Small Molecule to Target LGR4 for Oncology and Osteoporosis | 85 | 1 |
| Product Description | 85 | 1 |
| Mechanism of Action | 85 | 1 |
| R&D Progress | 85 | 1 |
| Small Molecule to Target LGR5 for Esophageal Adenocarcinoma | 86 | 1 |
| Product Description | 86 | 1 |
| Mechanism of Action | 86 | 1 |
| R&D Progress | 86 | 1 |
| Small Molecule to Target LGR6 for Dermatology | 87 | 1 |
| Product Description | 87 | 1 |
| Mechanism of Action | 87 | 1 |
| R&D Progress | 87 | 1 |
| Small Molecule to Target MAS1 for Cognitive Impairments, Blood Pressure Abnormalities and Colon Cancer | 88 | 1 |
| Product Description | 88 | 1 |
| Mechanism of Action | 88 | 1 |
| R&D Progress | 88 | 1 |
| Small Molecule to Target MRGE for Pain | 89 | 1 |